ABCD renal position statements & update

People living with diabetes and kidney disease (DKD) have a much greater risk of both kidney failure and cardiovascular disease.
Management is complex and needs to take anaemia, foot, eye, and bone health into consideration
Management of lipids , blood pressure and glycaemia all require a tailored approach depending on the type of diabetes and extent of renal disease and co-morbidity

The updated ABCD Renal Association guidelines include information on new therapeutic approaches and suggest new evidence based strategies for managing DKD and post transplantation diabetes (PTDM).

Learning outcomes:

  • Aim for lower non HDL cholesterol with lipid lowering therapy in DKD (statins , ezetimibe, and less often fenofibrate and PCSK inhibitors)
  • Confirm hypertension with home readings, aim for BP 130-140/80-90 depending on albuminuric status – when preferential RAAS blockade , consider modest reduction eGFR if benefiting cardiac failure
  • Individualised HbA1c targets in DKD and wider use of gliflozins and GLP1 analogues with cardiorenal benefit independent of glycaemic lowering
  • Assess risk of PTDM and take this into consideration with immunosuppressive regime , with tailored glycaemic management and insulin for symptomatic hyerglycaemia

Tuesday 29 October 2019

17:30 - 18:10

ABCD

MDT Icon Blue

Speakers

Peter Winocour
Consultant Physician and Clinical Director, ENHIDE , East and North Herts NHS Trust , Past Chairman of Association of British Clinical Diabetologists (ABCD).